Considered the most lucrative Australian university research commercialisation agreement ever negotiated, the 2025 deal for exclusive rights to the University of Queensland’s virus clamp technology has huge potential for vaccine development. Pharmaceutical giant Sanofi bought the university’s spin-off company Vicebio, with the rights to the clamp technology, for US$1.15 billion (A$1.6 billion) up-front and potential on-going payments of …read more